VIRACTA THERAPEUTICS INC (VIRX) Stock Price & Overview
NASDAQ:VIRX • US92765F1084
Current stock price
The current stock price of VIRX is 0.0778 USD. Today VIRX is down by -48.65%. In the past month the price decreased by -56.02%. In the past year, price decreased by -87.45%.
VIRX Key Statistics
- Market Cap
- 3.092M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.10
- Dividend Yield
- N/A
VIRX Stock Performance
VIRX Stock Chart
VIRX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VIRX. When comparing the yearly performance of all stocks, VIRX is a bad performer in the overall market: 98.82% of all stocks are doing better.
VIRX Earnings
VIRX Forecast & Estimates
6 analysts have analysed VIRX and the average price target is 3.06 USD. This implies a price increase of 3833.16% is expected in the next year compared to the current price of 0.0778.
VIRX Groups
Sector & Classification
VIRX Financial Highlights
Over the last trailing twelve months VIRX reported a non-GAAP Earnings per Share(EPS) of -1.1. The EPS increased by 11.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -197.14% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VIRX Ownership
VIRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 355.432B | ||
| AMGN | AMGEN INC | 15.09 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.44 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.23 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VIRX
Company Profile
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. The company is headquartered in Cardiff-By-The-Sea, California and currently employs 26 full-time employees. The company went IPO on 2005-09-27. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The firm is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Company Info
IPO: 2005-09-27
VIRACTA THERAPEUTICS INC
2533 S Coast Hwy 101, Suite 210
Cardiff-by-the-Sea CALIFORNIA 94080 US
CEO: Parvinder Hyare
Employees: 40
Phone: 18584008470
VIRACTA THERAPEUTICS INC / VIRX FAQ
What does VIRACTA THERAPEUTICS INC do?
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. The company is headquartered in Cardiff-By-The-Sea, California and currently employs 26 full-time employees. The company went IPO on 2005-09-27. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The firm is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Can you provide the latest stock price for VIRACTA THERAPEUTICS INC?
The current stock price of VIRX is 0.0778 USD. The price decreased by -48.65% in the last trading session.
Does VIRX stock pay dividends?
VIRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of VIRX stock?
VIRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is VIRX stock listed?
VIRX stock is listed on the Nasdaq exchange.
Should I buy VIRX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VIRX.
Who owns VIRACTA THERAPEUTICS INC?
You can find the ownership structure of VIRACTA THERAPEUTICS INC (VIRX) on the Ownership tab.